The natural history of trachoma infection and disease in a Gambian cohort with frequent follow-up

PLoS Neglected Tropical Diseases

Volumn 2, Issue 12, 2008, Pages

  Grassly, Nicholas C ^a   Ward, Michael E ^b   Ferris, Shirley ^b   Mabey, David C ^c   Bailey, Robin L ^c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ANAMNESIS; ARTICLE; CHILD; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; DEMOGRAPHY; DISEASE ACTIVITY; DISEASE DURATION; FOLLOW UP; GAMBIA; HIDDEN MARKOV MODEL; HUMAN; IMMUNOLOGICAL PARAMETERS; INFANT; INFLAMMATION; MAJOR CLINICAL STUDY; MEDICAL EXAMINATION; REINFECTION; SENSITIVITY AND SPECIFICITY; COHORT ANALYSIS; DISEASE TRANSMISSION; HEALTH SURVEY; IMMUNOLOGY; LACRIMAL FLUID; PATHOPHYSIOLOGY; PROBABILITY; STATISTICAL MODEL; TIME; TRACHOMA;

CHLAMYDIA TRACHOMATIS; COHORT STUDIES; FOLLOW-UP STUDIES; GAMBIA; HEALTH SURVEYS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIKELIHOOD FUNCTIONS; MARKOV CHAINS; TEARS; TIME FACTORS; TRACHOMA;

EID: 65549125432     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000341     Document Type: Article

References (46)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844-851.
2. Solomon AW, Holland MJ, Alexander ND, Massae PA, Aguirre A, et al. (2004) Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 351: 1962-1971.
3. Chidambaram JD, Alemayehu W, Melese M, Lakew T, Yi E, et al. (2006) Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 295: 1142-1146.
4. Burton MJ, Holland MJ, Makalo P, Aryee EAN, Alexander NDE, et al. (2005) Re-emergence of Chlamydia trachomatis infection after mass anitbiotic treatment of a trachoma endemic Gambian community: a longitudinal study. Lancet 365: 1321-1328.
5. West SK, Munoz B, Mkocha H, Holland MJ, Aguirre A, et al. (2005) Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 366: 1296-1300.
6. Lietman T, Porco T, Dawson CR, Blower S (1999) Global elimination of trachoma: How frequently should we administer mass chemotherapy? Nat Med 5: 572-576.
7. Darville T (2006) Immunology of Chlamydia trachomatis infections and prospects for the development of a vaccine. In: Chernesky M, Caldwell H, Christiansen G, Clarke IN, Kaltenboeck B, et al., eds. Ontario, Canada. International Chlamydia Symposium. pp 347-356.
8. Woolridge RL, Grayston JT, Chang IH, Yang CY, Cheng KH (1967) Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan. Am J Ophthalmol 63: Suppl: 1650-1655.
9. Wright HR, Taylor HR (2005) Clinical examination and laboratory tests for estimation of trachoma prevalence in a remote setting: what are they really telling us? Lancet Infect Dis 5: 313-320.
10. Morrison RP, Caldwell HD (2002) Immunity to murine chlamydial genital infection. Infect Immun 70: 2741-2751.
11. Taylor HR, Johnson SL, Prendergast RA, Schachter J, Dawson CR, et al. (1982) An animal model of trachoma 2. The importance of repeated reinfection. Invest Ophthalmol Vis Sci 23: 507-515.
12. Thygeson P (1934) The etiology of inclusion blennorrhea. Am J Ophthalmol 17: 1019-1035.
13. Thygeson P, Hanna L, Dawson C, Zichosch J, Jawetz E (1962) Inoculation of human volunteer with egg-grown inclusion conjunctivitis virus. Am J Ophthalmol 53: 786-795.
14. Jawetz E, Rose L, Hanna L, Thygeson P (1965) Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA 194: 620-632.
15. Mitsui Y, Konishi K, Nishimura A, Kajima M, Tamura O, et al. (1962) Experiments in Human Volunteers with Trachoma and Inclusion Conjunctivitis Agent. Br J Ophthalmol 46: 651-659.
16. Jones BR, Collier LH (1962) Inoculation of man with inclusion Blennorrhea virus. Ann NY Acad Sci 98: 212-228.
17. Cohen CR, Koochesfahani KM, Meier AS, Shen CX, Karunakaran K, et al. (2005) Immunoepidemiologic profile of Chlamydia trachomatis infection: Importance of heat-shock protein 60 and interferon-gamma. J Infect Dis 192: 591-599.
18. Molano M, Meijer CJLM, Weiderpass E, Arslan A, Posso H, et al. (2005) The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: A 5-year follow-up study. J Infect Dis 191: 907-916.
19. Caldwell HD, Wood H, Crane D, Bailey R, Jones RB, et al. (2003) Polymorphisms in Chlamydia trachomatis tryptophan synthase genes differentiate between genital and ocular isolates. J Clin Invest 111: 1757-1769.
20. Bailey R, Duong T, Carpenter R, Whittle H, Mabey D (1999) The duration of human ocular Chlamydia trachomatis infection is age dependent. Epidemiol Infect 123: 479-486.
21. Dawson CR, Jones BR, Tarizzo ML (1981) A guide to trachoma control. Geneva: WHO.
22. Ward ME, Ferris S, Mabey D, Bailey R (1994) Determination of the epitopic specificity of ocular antibodies to C trachomatis on low volume tear fluids using amplified EIA. In: Proceedings of the 8th International Symposium on Human Chlamydial Infections. Orfila J, et al., ed. Bologna, Italy.
23. Thylefors B, Dawson CR, Jones BR, West SK, Taylor HR (1987) A simple system for the assessment of trachoma and its complications. Bull WHO 65: 477-483.
24. Gentleman RC, Lawless JF, Lindsey JC, Yan P (1994) Multistate Markov-models for analyzing incomplete disease history data with illustrations for HIV disease. Stat Med 13: 805-821.
25. MacDonald IL, Zucchini W (1997) Hidden Markov and other models for discrete-valued time series. London: Chapman & Hall.
26. Jackson C (2006) Multi-state modelling with R: the msm package. (http://cran.r-project.org/). 0.7.4 ed.
27. Marshall G, Jones RH (1995) Multi-state models and diabetic retinopathy. Stat Med 14: 1975-1983.
28. Kalbfleisch JD, Lawless JF (1985) The analysis of panel data under a Markov assumption. J Am Statist Assoc 80: 863-871.
29. Wilks SS (1938) The large-sample distribution of the likelihood-ratio for testing composite hypotheses. Ann Math Stat 9: 60-62.
30. Bailey RL, Kajbaf M, Whittle HC, Ward ME, Mabey DCW (1993) The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection-IgG antibodies are not protective. Epidemiol Infect 111: 315-324.
31. Bailey RL, Arullendran P, Whittle HC, Mabey DCW (1993) Randomized controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 342: 453-456.
32. Solomon AW, Holland MJ, Burton MJ, West SK, Alexander NDE, et al. (2003) Strategies for control of trachoma: observational study with quantitative PCR. Lancet 362: 198-204.
33. Bailey RL, Hampton TJ, Hayes LJ, Ward ME, Whittle HC, et al. (1994) Polymerase chain reaction for the detection of ocular chlamydial infection in Trachoma endemic communities. J Infect Dis 170: 709-712.
34. Bobo LD, Novak N, Munoz B, Hsieh YH, Quinn TC, et al. (1997) Severe disease in children with trachoma is associated with persistent Chlamydia trachomatis infection. J Infect Dis 176: 1524-1530.
35. Bird M, Dawson CR, Schachter JS, Miao YH, Shama A, et al. (2003) Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? J Infect Dis 187: 1669-1673.
36. Miller K, Schmidt G, Melese M, Alemayehu W, Yi E, et al. (2004) How reliable is the clinical exam in detecting ocular chlamydial infection? Ophthalmic Epidemiol 11: 255-262.
37. Burton MJ, Holland MJ, Jeffries D, Mabey DCW, Bailey RL (2006) Conjunctival chlamydial 16S ribosomal RNA expression in trachoma: Is chlamydial metabolic activity required for disease to develop? Clin Infect Dis 42: 463-470.
38. Burton MJ, Holland MJ, Faal N, Aryee EAN, Alexander NDE, et al. (2003) Which members of a community need antibiotics to control trachoma? Conjunctival Chlamydia trachomatis infection load in Gambian villages. Invest Ophth Vis Sci 44: 4215-4222.
39. Solomon AW, Harding-Esch E, Alexander NDE, Aguirre A, Holland MJ, et al. (2008) Two Doses of Azithromycin to Eliminate Trachoma in a Tanzanian Community. N Engl J Med 358: 1870-1871.
40. McCormack WM, Alpert S, Mccomb DE, Nichols RL, Semine DZ, et al. (1979) 15-month follow-up-study of women infected with Chlamydia trachomatis. New Engl J Med 300: 123-125.
41. Morre SA, van den Brule AJC, Rozendaal L, Boeke AJP, Voorhorst FJ, et al. (2002) The natural course of asymptomatic Chlamydia trachomatis infections: 45% clearance and no development of clinical PID after one-year follow-up. Intl J STD & AIDS 13: 12-18.
42. Munk C, Morre SA, Kjaer SK, Poll PA, Bock JE, et al. (1999) PCR-detected Chlamydia trachomatis infections from the uterine cervix of young women from the general population - Prevalence and risk determinants. Sex Transm Dis 26: 325-328.
43. Hsieh YH, Bobo LD, Quinn TC, West SK (2000) Risk factors for trachoma: 6-year follow-up of children aged 1 and 2 years. Am J Epidemiol 152: 204-211.
44. Gambhir M, Basanez M-G, Turner F, Kumaresan J, Grassly N (2007) Trachoma: transmission, infection, and control. Lancet Infect Dis 7: 420-427.
45. Burton MJ, Bowman RJC, Faal H, Aryee EAN, Ikumapayi UN, et al. (2006) The long-term natural history of trachomatous trichiasis in the Gambia. Invest Ophth Vis Sci 47: 847-852.
46. Michel CEC, Solomon AW, Magbanua JPV, Massae PA, Huang L, et al. (2006) Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study. Lancet 367: 1585-1590.